Deutsch English Français

Contact

EP1303293

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1303293

EP1303293 - SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE [Right-click to bookmark this link]
Former [2003/17]	APO-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
	[2008/24]
Status	No opposition filed within time limit Status updated on 09.10.2009 Database last updated on 03.06.2024
Most recent event Tooltip	09.10.2009	No opposition filed within time limit	published on 11.11.2009 [2009/46]
Applicant(s)	For all designated states Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 / US
	[N/P]
Former [2008/38]	For all designated states Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990 / US
Former [2003/17]	For all designated states GENENTECH, INC. 1 DNA Way South San Francisco California 94080 / US
Inventor(s)	01 / ESCANDON, Enrique 10 Garden Ct. Apt. 2 Belmont, CA 94002 / US
	02 / FOX, Judith, A. 1531 Golden Gate Avenue San Francisco, CA 94115 / US
	03 / KELLEY, Sean, K. 3915 Edison Street San Mateo, CA 94403 / US
	04 / XIANG, Hong 558 Driscoll Place Palo Alto, CA 94306 / US
	[2003/17]
Representative(s)	Kiddle, Simon John, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB
	[N/P]
Former [2003/17]	Kiddle, Simon John, et al Mewburn Ellis, York House, 23 Kingsway London WC2B 6HP / GB
Application number, filing date	01957295.7	27.07.2001
	[2003/17]
	WO2001US23691
Priority number, date	US20000221256P	27.07.2000 Original published format: US 221256 P
	[2003/17]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO0209755
	Date:	07.02.2002
	Language:	EN
	[2002/06]
	Type:	A2 Application without search report
	No.:	EP1303293
	Date:	23.04.2003
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 07.02.2002 takes the place of the publication of the European patent application.
	[2003/17]
	Type:	B1 Patent specification
	No.:	EP1303293
	Date:	03.12.2008
	Language:	EN
	[2008/49]
Search report(s)	International search report - published on:	EP	13.02.2003
Classification	IPC:	A61K38/17, A61K39/395, A61P35/00, A61P37/00	[2008/26]
	CPC:	A61K39/39541 (EP); A61K31/4745 (EP); A61K38/177 (EP); A61P35/00 (EP); A61P37/00 (EP); A61P43/00 (EP)
	C-Set:	A61K31/4745, A61K2300/00 (EP); A61K38/177, A61K2300/00 (EP); A61K39/39541, A61K2300/00 (EP)
	Former IPC [2003/17]	A61K38/17, A61K39/395, A61P35/00, A61P37/00, // (A61K39/395, 31:47),(A61K38/17, 31:47)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/17]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	SEQUENTIELLE VERABREICHUNG VON CPT-11 UND APO-2L POLYPEPTID	[2008/24]
	English:	SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE	[2008/24]
	French:	ADMINISTRATION SEQUENTIELLE DE CPT-11 ET D'APO 2L POLYPEPTIDE	[2008/24]
	Former [2003/17]	APO-2L REZEPTORAGONIST UND CPT-11 SYNERGIE
	Former [2003/17]	APO-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
	Former [2003/17]	SYNERGISME DE L'AGONISTE DU RECEPTEUR DE L'APO-2L ET DU CPT-11
Biological material	This application mentions deposited biological material, check the file for details
Entry into regional phase	17.02.2003	National basic fee paid
	17.02.2003	Designation fee(s) paid
	17.02.2003	Examination fee paid
Examination procedure	12.02.2002	Request for preliminary examination filed International Preliminary Examining Authority: EP
	17.02.2003	Examination requested [2003/17]
	13.10.2006	Despatch of a communication from the examining division (Time limit: M06)
	31.05.2007	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	07.08.2007	Reply to a communication from the examining division
	02.06.2008	Communication of intention to grant the patent
	06.10.2008	Fee for grant paid
	06.10.2008	Fee for publishing/printing paid
Divisional application(s)	EP08017358.6 / EP2014303
Opposition(s)	04.09.2009	No opposition filed within time limit [2009/46]
Request for further processing for:	07.08.2007	Request for further processing filed
	07.08.2007	Full payment received (date of receipt of payment) Request granted
	20.08.2007	Decision despatched
Fees paid	Renewal fee
	14.07.2003	Renewal fee patent year 03
	14.07.2004	Renewal fee patent year 04
	13.07.2005	Renewal fee patent year 05
	12.07.2006	Renewal fee patent year 06
	13.07.2007	Renewal fee patent year 07
	14.07.2008	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[A]WO9937684 (GENENTECH INC [US]) [A] 6-9,21,26 * example - * * claim - *;
		[Y]WO9948527 (GENENTECH INC [US]) [Y] 16 * page 30, line 23 * * example 1 * * claim - *;
		[PX]WO0075191 (GENENTECH INC [US]) [PX] 1-27 * example - * * claim - *;
		[XY] - A. ASHKENAZI ET AL., "Safety and antitumor activity of recombinant soluble Apo2 ligand.", JOURNAL OF CLINICAL INVESTIGATION, New York, NY, USA, (199907), vol. 104, no. 2, pages 155 - 162, XP000973369 [X] 1-5,15,17-20,22-25 * abstract * * page 161, column L, line 2 - line 16 * * page 162, column L, line 6 - line 29 * [Y] 6-13,16,21,26,27 DOI: http://dx.doi.org/10.1172/JCI6926
		[Y] - T. GRIFFITH ET AL., "Functional analysis of TRAIL receptors using monoclonal antibodies.", THE JOURNAL OF IMMUNOLOGY, Baltimore, MD, USA, (19990301), vol. 162, pages 2597 - 2605, XP000918935 [Y] 6-13,21,26,27 * page 2600, column L, line 1 - column R, line 5 *
		[X] - B. GLINIAK ET AL., "Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.", CANCER RESEARCH, Baltimore, MD, USA, (19991215), vol. 59, no. 24, pages 6153 - 6158, XP000941885 [X] 1-5,15,17-20,22-25 * the whole document *
		[X] - B. GLINIAK ET AL., "Enhanced therapeutic efficacy of TRAIL/Apo2L in combination with CPT-11 in the treatment of human tumor xenografts.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, Philadelphia, PA, USA, (200003), vol. 41, page 70, XP002207071 [X] 1-5,17-20,22-25 * abstract #450 *
		[A] - R. PITTI ET AL., "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Baltimore, MD, USA, (19960531), vol. 271, no. 22, pages 12687 - 12690, XP002031265 [A] 1-5,18-20,23-25 * abstract * * figure 1 * DOI: http://dx.doi.org/10.1074/jbc.271.22.12687
		[PX] - H. XIANG ET AL., "Combined Apo2L/TRAIL and CPT-11 enhanced tumor cell apoptosis.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, Philadelphia, PA, USA, (200103), vol. 42, page 643, XP002207072 [PX] 1-5,17-20,22-25 * abstract #3457 *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p